Vor Biopharma (NYSE:VOR) Receives Outperform Rating from Wedbush

Shares of Vor Biopharma (NYSE:VOR) have received renewed attention as Wedbush analysts maintained their "outperform" rating for the company. In a report shared on Friday, they set a target price of $11.00 for the stock.

Other analysts have also weighed in on Vor Biopharma. For instance, Robert W. Baird has lowered its price target on the stock from $22.00 to $14.00 while also rating it as "outperform." Meanwhile, JMP Securities reaffirmed a "market outperform" rating and issued a price target of $12.00 in a report dated September 6. Barclays, on the other hand, lowered their price objective from $10.00 to $3.00 but still rated the stock as "overweight." Lastly, HC Wainwright reaffirmed a "buy" rating with a price target set at $17.50. According to MarketBeat.com, seven research analysts have currently rated the stock as a buy, leading to an average rating of "Buy" and a mean price target of approximately $11.36.

Recent Stock Performance

In trading on Friday, the stock of Vor Biopharma increased by 14.9%, reaching a price of $0.96 during mid-day trading. A total of 781,468 shares changed hands, amid a typical trading volume of 504,849. The company's share price has a 50-day moving average of $0.80 and a two-hundred-day moving average standing at $1.08. With a market capitalization of $65.53 million, the stock carries a price-to-earnings ratio of -0.55 and a beta of -0.40. In the past year, shares reached as low as $0.63 and peaked at $3.14.

Vor Biopharma recently released its earnings results on August 8, where it reported an earnings per share (EPS) of ($0.41), aligning with the analysts' consensus estimate of ($0.41). Analysts predict that Vor Biopharma will report an average EPS of -1.51 for the current fiscal year.

Institutional Investor Movements

Institutional investors have also been active regarding Vor Biopharma's stock. Notably, Acadian Asset Management LLC increased its holdings in the company by 51.4% in the second quarter, owning now 81,305 shares valued at $79,000 after acquiring an additional 27,597 shares. Additionally, HSBC Holdings PLC boosted its stake by 177.0%, now owning 49,038 shares worth $51,000 after buying an extra 31,333 shares. Exchange Traded Concepts LLC raised its position in Vor Biopharma by 40.8% during the third quarter, now holding 165,805 shares valued at $116,000 after an increase of 48,017 shares. Other institutional movements include Cubist Systematic Strategies LLC, which purchased a new stake valued at around $53,000, and Point72 Asia Singapore Pte. Ltd., acquiring a new position valued at about $63,000. Overall, institutional investors and hedge funds own about 97.29% of the company’s stock.

About Vor Biopharma

Vor Biopharma Inc is a clinical-stage company focusing on cell and genome engineering. The lead product, tremtelectogene empogeditemcel (trem-cel), is an engineered hematopoietic stem cell (eHSC) candidate currently undergoing phase 1/2 trials aimed at treating acute myeloid leukemia (AML) and other hematological malignancies.

Vor, Biopharma, Stock